Welcome to Korean Medical Index (KMI), the premier digital intelligence platform dedicated to bridging the information gap between South Korea’s rapidly evolving biotechnology ecosystem and the global healthcare market.
South Korea has emerged as an undisputed powerhouse of life sciences innovation, characterized by ground-breaking AI-driven therapeutics, robust clinical trial infrastructures, and high-value multinational licensing agreements. However, due to linguistic and geographic fragmentation, much of this fast-moving data remains trapped within domestic networks.
Korean Medical Index solves this information asymmetry. Operating a continuous, automated analytical pipeline, KMI translates raw domestic breakthroughs into institutional-grade global market reports. We serve international asset managers, biotechnology venture capitalists, pharmaceutical business development executives, and life sciences researchers who require real-time, objective visibility into Asia’s most dynamic bio-health corridor.